In the present study, we thus aimed at exploring the impact of switching from isCGM to rtCGM systems on glycemic control in DT1 patients treated by continuous subcutaneous insulin infusion (CSII) or multiple daily insulin injections (MDI), having poor glycemic control either due to hypoglycemia issue or/and to elevated HbA1c. The gene discussed is INS; the disease is Hypoglycemia.